(3R,4R)-3,4-bis((tert-butyl(dimethyl)silyl)oxy)piperidine → 4-{4-[(3RS,4SR)-3,4-Bis-(tert-butyl-dimethyl-silanyloxy)-piperidin-1-yl]-butyl}-1-[(E)-3-(3,4-dichloro-phenyl)-acryloyl]-[1,4]diazepan-5-one

Participants

Role	Name	HCID	Charge
Reactant	(3R,4R)-3,4-bis((tert-butyl(dimethyl)silyl)oxy)piperidine	HCID 10893352	—
Reactant	1-[(E)-3-(3,4-dichloro-phenyl)-acryloyl]-4-(4-iodo-butyl)-[1,4]diazepan-5-one	HCID 68433016	—
Product	4-{4-[(3RS,4SR)-3,4-Bis-(tert-butyl-dimethyl-silanyloxy)-piperidin-1-yl]-butyl}-1-[(E)-3-(3,4-dichloro-phenyl)-acryloyl]-[1,4]diazepan-5-one	HCID 68432310	—

Reaction Steps

In analogy to the procedure described in example 163A, 1-[(E)-3-(3,4-dichloro-phenyl)-acryloyl]-4-(4-iodo-butyl)-[1,4]diazepan-5-one (example 9B) and (trans)-(rac)-3,4-Bis-(tert-butyl-dimethyl-silanyloxy)-piperidine (intermediate 26) gave the title compound as colorless oil.

Provenance & Evidence

DOI	10.6084/m9.figshare.5104873.v1
Patent number	US07632829B2
Source dataset	uspto-grants-2009_12
ORD ID	ord-ffc88ba9ad0b44b18172864912a4b4e6
Source note	uspto-grants-2009_12